MONITORING OF CONTRAST AGENT-INDUCED TOXICITY IN A TERTIARY HEALTH-CARE CENTER
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i6.50719Keywords:
Contrast Agent, Contrast-Enhanced MRI, Contrast-Enhanced CT, Contrast-Induced Nephropathy, Gadolinium, IohexolAbstract
Objective: The objective of the study is to monitor radiological contrast agent-induced toxicity in patients and compare the toxicity and safety profiles of different radiological contrast agents.
Methods: This is an open-label, prospective, observational study conducted in a tertiary care hospital in April 2021 and September 2021. The study assessed the incidence of contrast-induced adverse events in different radiological procedures, i.e., contrast-enhanced computerized tomography (CECT) scans and contrast-enhanced magnetic resonance imaging (CEMRI). Adverse drug reactions (ADRs) were recorded using the standard central drug standard control organization ADR reporting form. Causality assessment of the ADRs was done using Naranjo’s scale while severity assessment was measured using the Modified Hartwig and Siegel scale.
Results: The baseline characteristics of patients were almost similar in both groups. The mean age and gender distribution of the patients were not significantly different among both groups. For the adverse reaction in CECT, the male-to-female ratio was 1.88, and for CEMRI, it was 1.61. The ADRs due to CEMRI and CECT were mild in severity. The results showed that ADRs between contrast-enhanced MRI and contrast-enhanced CT were not significantly different.
Conclusion: Based on the results obtained, we concluded that the contrast agents used in the radio-diagnostic procedures are safe, and further research in this field is of fundamental importance.
Downloads
References
Lightfoot CB, Abraham RJ, Mammen T, Abdolell M, Kapur S, Abraham RJ. Survey of radiologists’ knowledge regarding the management of severe contrast material-induced allergic reactions. Radiology. 2009;251(3):691-6. doi: 10.1148/radiol.2513081651, PMID 19474374
Thomson KR, Varma DK. Safe use of radiographic contrast media. Aust Prescr. 2010;33(1):19-22. doi: 10.18773/austprescr.2010.006
Violon D. Renal failure and iodinated contrast media. A review. JBR-BTR. 1999 Apr;82(2):57-62. PMID 10874391
McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al. Contrast-Induced acute kidney injury. J Am Coll Cardiol. 2016;68(13):1465-73. doi: 10.1016/j.jacc.2016.05.099, PMID 27659469
Nyman U, Elmstaåhl B, Leander P, Nilsson M, Golman K, Almeén T. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology. 2002;223(2):311-8; discussion 328-9. doi: 10.1148/ radiol.2232010221, PMID 11997530
Saini S, Bhardwaj BY, Chhabra J, Kumar M, Pahwa R. In vivo monitoring strategies for evaluation of floating drug delivery systems. Int J Appl Pharm. 2022;14(6):28-33. doi: 10.22159/ijap.2022v14i6.45906
Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol. 2001 Jun;176(6):1385-8. doi: 10.2214/ajr.176.6.1761385, PMID 11373197
Gulani V, Calamante F, Shellock F, Kanal E,Reeder S, Reeder S. Gadolinium Deposition in the Brain: Summary of Evidence and
Recommendations. Lancet Neurol. 2017;16(7):564-70.
Maddox TG. Adverse reactions to contrast material: Recognition, prevention, and treatment. Am Fam Physician. 2002 Oct 1;66(7):1229-34. PMID 12387435
Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: A primer for the non-radiologist. Mayo Clin Proc. 2012 Apr;87(4):390-402. doi: 10.1016/j. mayocp.2012.01.012, PMID 22469351
Saljoughian M. Intravenous radiocontrast media: A review of allergic reactions. US Pharm. 2012;37(5):HS-14-6.
Andreucci M, Faga T, Serra R, De Sarro G, Michael A. Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf. 2017 May 22;9:25-37. doi: 10.2147/DHPS. S122207, PMID 28579836
Bruder O, Schneider S, Nothnagel D, Pilz G, Lombardi M, Sinha A, et al. Acute adverse reactions to gadolinium-based contrast agents in CMR: Multicenter experience with 17,767 patients from the EuroCMR registry. JACC Cardiovasc Imaging. 2011 Nov;4(11):1171-6. doi: 10.1016/j.jcmg.2011.06.019, PMID 22093267
Stacul F. Current iodinated contrast media. Eur Radiol. 2001;11(4):690-7. doi: 10.1007/s003300000620, PMID 11354768
Lee H, Song S, Oh YK, Kang WK, Kim E. Is gender still a predisposing factor in contrast-media associated adverse drug reactions? A systematic review and meta-analysis of randomized trials and observational studies. Eur J Radiol. 2017;89:81-9. doi: 10.1016/j.ejrad.2017.01.015, PMID 2826755416. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. doi: 10.1038/clpt.1981.154, PMID 7249508
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32. doi: 10.1093/ajhp/49.9.2229, PMID 1524068
Lubis DA, Yunir EM, Mulyadi R, Lubis AM, Koesnoe S. Correlation between serum ferritin, transferrin saturation and pituitary MRI T2 relaxation times and FSH, LH and testosterone levels in male transfusion-dependent thalassemia patients. Int J Appl Pharm. 2020;12(3):28-32. doi: 10.22159/ijap.2020.v12s3.39464
Pomara C, Pascale N, Maglietta F, Neri M, Riezzo I, Turillazzi E. Use of contrast media in diagnostic imaging: Medico-legal considerations. Radiol Med. 2015;120(9):802-9. doi: 10.1007/s11547-015-0549-6, PMID 26082145
Kaller MO, An J. Contrast agent toxicity. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021 Jan. PMID 30725844
Bettmann MA. Frequently asked questions: Iodinated contrast agents. Radiographics. 2004; 24(Suppl 1):S3-10. doi: 10.1148/rg.24si045519, PMID 15486247
Hinson JS, Ehmann MR, Fine DM, Fishman EK, Toerper MF, Rothman RE, et al. Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med. 2017 May;69(5):577-86.e4. doi: 10.1016/j.annemergmed.2016.11.021, PMID 28131489
Aycock RD, Westafer LM, Boxen JL, Majlesi N, Schoenfeld EM, Bannuru RR. Acute kidney injury after computed tomography: A meta-analysis. Ann Emerg Med. 2018 Jan;71(1):44-53.e4. doi: 10.1016/j. annemergmed.2017.06.041, PMID 28811122
Spampinato MV, Abid A, Matheus MG. Current radiographic iodinated contrast agents. Magn Reson Imaging Clin N Am. 2017;25(4):697-704. doi: 10.1016/j.mric.2017.06.003, PMID 28964459
Cha MJ, Kang DY, Lee W, Yoon SH, Choi YH, Byun JS, et al. Hypersensitivity reactions to iodinated contrast media: A multicenter study of 196 081 patients. Radiology. 2019;293(1):117-24. doi: 10.1148/ radiol.2019190485, PMID 31478801
Pelagatti V, Bagheri H, Fernandez P, Railhac N, Bregeon C, Railhac JJ, et al. Adverse effects of contrast media: Results of a 6 months study. Therapies. 2000;55(3):391-4.
Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011 Feb;196(2):W138-43. doi: 10.2214/AJR.10.4885, PMID 21257854
Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: Retrospective review of 456,930 doses. AJR Am J Roentgenol. 2009 Oct;193(4):1124-7. doi: 10.2214/AJR.09.2520, PMID 19770337
Published
How to Cite
Issue
Section
Copyright (c) 2024 Mantasha Rehmani, Irfan Ahmad Khan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
